In 2023, there were **** deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost ** deaths per 100,000 people in the early 2000s, and about ** deaths in 1980. Prevalence of diabetes In 2022, around *** percent of the adult population in the U.S. had diabetes. In total, around ** million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

The death rate due to diabetes mellitus in Canada has fallen since 2000 from **** per 100,000 population to **** deaths per 100,000 population in 2023. Diabetes is the seventh leading cause of death in Canada. In the United States, it was responsible for **** deaths per 100,000 population in 2023. About diabetesDiabetes mellitus is due to an insufficient production of insulin within the pancreas or a lack of response from the body to the insulin that is produced. The most common type of diabetes mellitus is type II diabetes, which accounts for over ** percent of diabetes cases in the United States. Type II diabetes occurs when cells in the body are unresponsive to insulin and may lead to a decrease in insulin production as well. Prevention and costsOne of the greatest problems with type II diabetes is that it can lead to many different complications such as some types of cancer, cardiovascular disease, and even amputations. This type of diabetes is largely associated with overweight and obese populations and those who are physically inactive. It is also considered a preventable disease by maintaining healthy diets and balanced lifestyles. Health care expenditures to treat diabetes in the United States amounted to around ***** billion U.S. dollars as of 2024, while China, a country with a lower diabetes incidence but a much larger population, spent about *** billion U.S. dollars.

Different levels of hypoglycemia-related relative risks of all-cause and cardiovascular mortality by various mean HbA1c in patients with type 2 diabetes.

AimTo report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019.MethodsWe used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs).ResultsIn 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs.ConclusionLow and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions.

Diabetes continues to be a significant global health concern, with the Western Pacific region reporting the highest number of diabetes-related deaths in 2024, with around 1.2 million. This stark figure underscores the urgent need for improved diabetes prevention and management strategies worldwide. North America and the Caribbean followed with an estimated 526,000 deaths, while Africa is had the lowest number at 216,000. Regional disparities and global impact The prevalence of diabetes varies significantly across regions, reflecting differences in healthcare systems, lifestyle factors, and genetic predispositions. In the United States, the death rate from diabetes mellitus was 22.4 per 100,000 people in 2023, with 8.4 percent of the adult population living with the condition. Canada has seen a slight decrease in its diabetes-related death rate, falling from 21.8 per 100,000 in 2000 to 18.1 per 100,000 in 2023. These figures highlight the ongoing challenges in managing diabetes, even in countries with advanced healthcare systems. European landscape and global context Within Europe, Germany reported the highest number of diabetes-related deaths in 2024, with nearly 63,000 fatalities among adults aged 20 to 79 years. Italy followed closely with around 62,400 deaths. However, Czechia reported the highest mortality rates in Europe as of 2022, with 43.4 diabetes deaths per 100,000 population overall. On a global scale, diabetes remains a major health concern, with 19 percent of adults worldwide identifying it as one of the biggest health problems in their country.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England and the Welsh Government. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This short report details the top-level findings for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. The top-level findings below, along with supporting data at Clinical Commissioning Group (CCG), Local Health Board (LHB), GP practice and specialist diabetes service have been made available to provide data back to services in a timely manner that can help drive improvements in the quality of diabetes care locally. The full report, scheduled for 2020, will contain full key findings, recommendations and results of new analyses into HbA1c check frequencies and blood glucose drug cohorts. We will communicate to users when the date for this report has been finalised. A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

The objective of this study was to compare the effect of diabetes and pathologies potentially related to diabetes on the risk of infection and death from COVID-19 among people from Highly-Developed-Country (HDC), including Italians, and immigrants from the High-Migratory-Pressure-Countries (HMPC). Among the population with diabetes, whose prevalence is known to be higher among immigrants, we compared the effect of body mass index among HDC and HMPC populations. A population-based cohort study was conducted, using population registries and routinely collected surveillance data. The population was stratified into HDC and HMPC, according to the place of birth; moreover, a focus was set on the South Asiatic population. Analyses restricted to the population with type-2 diabetes were performed. We reported incidence (IRR) and mortality rate ratios (MRR) and hazard ratios (HR) with 95% confidence interval (CI) to estimate the effect of diabetes on SARS-CoV-2 infection and COVID-19 mortality. Overall, IRR of infection and MRR from COVID-19 comparing HMPC with HDC group were 0.84 (95% CI 0.82–0.87) and 0.67 (95% CI 0.46–0.99), respectively. The effect of diabetes on the risk of infection and death from COVID-19 was slightly higher in the HMPC population than in the HDC population (HRs for infection: 1.37 95% CI 1.22–1.53 vs. 1.20 95% CI 1.14–1.25; HRs for mortality: 3.96 95% CI 1.82–8.60 vs. 1.71 95% CI 1.50–1.95, respectively). No substantial difference in the strength of the association was observed between obesity or other comorbidities and SARS-CoV-2 infection. Similarly for COVID-19 mortality, HRs for obesity (HRs: 18.92 95% CI 4.48–79.87 vs. 3.91 95% CI 2.69–5.69) were larger in HMPC than in the HDC population, but differences could be due to chance. Among the population with diabetes, the HMPC group showed similar incidence (IRR: 0.99 95% CI: 0.88–1.12) and mortality (MRR: 0.89 95% CI: 0.49–1.61) to that of HDC individuals. The effect of obesity on incidence was similar in both HDC and HMPC populations (HRs: 1.73 95% CI 1.41–2.11 among HDC vs. 1.41 95% CI 0.63–3.17 among HMPC), although the estimates were very imprecise. Despite a higher prevalence of diabetes and a stronger effect of diabetes on COVID-19 mortality in HMPC than in the HDC population, our cohort did not show an overall excess risk of COVID-19 mortality in immigrants.

Participant demographics by prediabetes and type 2 diabetes status.

The age-standardized death rate and temporal trends of T2DM in 1990 and 2019.

A retrospective cohort study was conducted including adult patients (age ≥ 18 years) with a diagnosis of type 2 diabetes within the study period of January 1, 2009 through December 31, 2016, living in the Cuyahoga and the surrounding 7-county region, and seen within the Cleveland Clinic system at least once within the 8-year study period. Patients with type 1 diabetes were excluded. Data were extracted from the enterprisewide electronic health record (EHR) at Cleveland Clinic (Epic Verona, Wisconsin).

Objective To assess the trends in T2DM burden attributable to tobacco exposure in China and globally from 1990 to 2021, and to project the future burden, providing evidence to support integrated strategies for tobacco control and diabetes prevention. Methods Data on T2DM deaths, disability-adjusted life years (DALYs), age-standardized death rates (ASDR), and age-standardized DALY rates attributable to tobacco, active smoking, and secondhand smoke from 1990 to 2021 were obtained from the Global Burden of Disease Study 2021 (GBD 2021). Joinpoint regression models were used to analyze temporal trends in standardized rates. The Das Gupta decomposition method was applied to quantify the contributions of population growth, population aging, and epidemiological changes to the overall burden. A Bayesian age-period-cohort (BAPC) model was used to forecast trends in attributable burden from 2022 to 2035. Results From 1990 to 2021, global T2DM deaths and DALYs attributable to tobacco exposure increased by 94.26% and 136.94%, respectively, while the increases in China were even greater at 128.79% and 165.03%. Over the same period, the global ASDR declined, whereas the DALY rate showed an overall upward trend, with a more pronounced increase observed in China. The burden related to active smoking was predominantly seen in males, while the burden from secondhand smoke was more prominent among females. Burden peaked among individuals aged 55–74 years, with a slight delay in peak age in China compared to global patterns. Trend analysis showed that although ASDR declined in certain periods, DALY rates continued to rise throughout most of the time span. Decomposition analysis identified population growth and aging were the main contributors to the increasing burden. BAPC projections indicated that both attributable deaths and DALYs will continue to rise globally and in China through 2035, with sharper increases projected for China. Conclusions From 1990 to 2021, the T2DM burden attributable to tobacco exposure increased substantially in both China and globally, with notable sex and age disparities. The burden is projected to continue growing in the coming years. These findings underscore the need for strengthened and integrated tobacco control and diabetes prevention strategies, particularly targeting smoking among middle-aged and older men and secondhand smoke exposure among women, to curb the rising T2DM burden.

Objective: To develop and validate models allowing the prediction of major adverse chronic renal outcomes (MACRO) in patients with type 2 diabetes mellitus (T2DM) using insurance claims data. Methods: The Optum Integrated Real World Evidence Electronic Health Records and Claims de-identified database (10/01/2006–09/30/2016) was used to identify T2DM patients ≥50 years old. Risk factors were assessed over a 12-month baseline period, and MACRO were subsequently assessed until the end of data availability, continuous enrollment, or death. Separate models were built for moderate-to-severe diabetic kidney disease (DKD), end-stage renal disease (ESRD), and renal death. A random split-sample approach was employed, where 70% of the sample served for model development (training set) and the remaining 30% served for validation (testing set). C-statistics were used to assess model performance. Results: A total of 160,031 patients were included. Risk factors associated with MACRO for all models included adapted diabetes complications severity index, heart failure, anemia, diabetic nephropathy, and CKD. C-statistics ranged between 0.70 (moderate-to-severe DKD) and 0.84 (renal death) in the testing set. A substantial proportion (e.g. 88.7% for moderate-to-severe DKD) of patients predicted to be at high-risk of MACRO did not have diabetic nephropathy, proteinuria, or CKD at baseline. Conclusions: The models developed using insurance claims data could reliably predict the risk of MACRO in patients with T2DM and enabled patients at higher-risk of DKD to be identified in the absence of baseline diabetic nephropathy, CKD, or proteinuria. These models could help establish strategies to reduce the risk of MACRO in T2DM patients.

BackgroundHigh body mass index (BMI) plays a critical role in the initiation and development of type 2 diabetes (T2D). Up to now, far too little attention has been paid to the global burden of T2D attributable to high BMI. This study aims to report the deaths and disability-adjusted life years (DALYs) of T2D related to high BMI in 204 countries and territories from 1990 to 2019.MethodsData on T2D burden attributable to high BMI were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. The global cases, age-standardized rates of mortality (ASMR), and disability-adjusted life years (ASDR) attributable to high BMI were estimated by age, sex, geographical location, and socio-demographic index (SDI). The estimated annual percentage change (EAPC) was calculated to quantify the trends of ASMR and ASDR during the period 1990–2019.ResultsGlobally, there were 619,494.8 deaths and 34,422,224.8 DALYs of T2D attributed to high BMI in 2019, more than triple in 1990. Moreover, the pace of increase in ASMR and ASDR accelerated during 1990–2019, with EAPC of 1.36 (95% CI: 1.27 to 1.45) and 2.13 (95% CI: 2.10 to 2.17) separately, especially in men, South Asia, and low-middle SDI regions. Oceania was the high-risk area of standardized T2D deaths and DALYs attributable to high BMI in 2019, among which Fiji was the country with the heaviest burden. In terms of SDI, middle SDI regions had the biggest T2D-related ASMR and ASDR in 2019.ConclusionThe global deaths and DALYs of T2D attributable to high BMI substantially increased from 1990 to 2019. High BMI as a major public health problem needs to be tackled properly and timely in patients with T2D.

According to preliminary data between January and October 2024, *** percent of deaths in the Philippines were caused by diabetes mellitus diseases. Deaths from such illnesses peaked in 2020. Diabetes mellitus is diagnosed when glucose is high in the blood.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded and managed by NHS England, in partnership with Diabetes UK. The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for the full 2023-24 audit period (1 January 2023 – 31 March 2024); presented for England primary care, Wales primary care and specialist services (hospital-based care), each with its own separate data file. Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the January 2023 to March 2024 cut of this data being taken in May 2024. Data from Wales was received in June 2024.

Tuberculosis (TB), a communicable disease, is currently a significant health problem in Thailand. Type 2 diabetes (T2D) is an indicator of poor TB outcomes; however, data according to specific antihyperglycemic use and tuberculosis outcomes in community hospital settings in Thailand remain limited. We aimed to determine TB mortality as well as explore the demographic and clinical risk factors among patients with pulmonary TB and underlying T2D. A retrospective cohort study was conducted between January 1, 2013, and December 31, 2020, to determine tuberculosis mortality and its risk factors among patients with T2D and pulmonary TB visiting three community hospitals, in central Thailand. T2D and pulmonary TB were determined according to the International Classification of Diseases, Tenth Revision codes presented in medical records. TB mortality data were reviewed and retrieved from the tuberculosis treatment cards. Patients were classified as “dead” when they died before completing treatment regardless of the causes. Multivariable cox proportional regression analysis was performed to obtain the adjusted hazard ratios (AHR) and 95% confidence interval (CI) of factors related to TB mortality. A total of 133 patients with T2D and pulmonary TB were enrolled in the present study; 74 (55.6%) participants were males. At baseline, the average age of participants was 57.29+12.51 years. During the study period, the TB mortality rate was 15.74 (95% CI 8.13-27.50) deaths per 100 person-years. The independent risk factors for TB mortality included age ≥70 years (AHR 5.45, 95% CI; 1.36-21.84), use of insulin (AHR 4.62, 95% CI; 1.11-19.21), and positive sputum test result at 1st follow-up (AHR 16.10, 95% CI; 2.10-123.40). TB mortality among patients with T2D should be emphasized. Insulin use may be a proxy indicator for poor glycemic control associated with mortality. Additionally, elderly patients should be closely observed for successful treatment as well as monitoring for any adverse events.

Local reports - breakdown of report 1 (Care Processes and Treatment Targets) and report 2 (Complications and Mortality) by PCT in the North West SHA. In addition to the National reports, the NDA has also produced PCT/LHB profile reports which present key PCT/LHB findings from the 2010-2011 audit for all age groups. The data used to produce the reports is extracted from GP practices in your PCT/LHB and is augmented by secondary care outpatient data and Hospital Episode Statistics and Patient Episode Data for Wales on diabetes related complications. The data is validated, processed and analysed to measure compliance with the National Service Framework (NSF) for Diabetes and NICE quality standards. The analysis contained in the PCT/LHB profile report is benchmarked against the national findings and provides some time trend analysis, allowing you to compare care and treatment results to findings from the 2009-2010 audit. For further information and recommended actions for commissioners please refer to the National Diabetes Audit 2010-2011 Report 1: Care Processes and Treatment Targets and National Diabetes Audit 2010-2011 Report 2: Complications and Mortality Note: NDA 2010-11- Reports Updated: The treatment target section of these reports were updated on 28/09/2012, an error in the data processing rule for HbA1c meant that patients who had their HbA1c values submitted as a percentage had not been included in the reports leading to a misreporting of HbA1c and treatment target bundle completion. This has now been corrected. No other figures were affected. Note: 2010-11 Report 1 PCT breakdowns were published on 28th September 2012.

In 2021, it was estimated that China had about 141 million diabetics aged from 20 to 79 years, which was the highest number of any country. The figure would very likely climb to 174 million by 2045. Diabetes is one of the leading death causes across the globe.

An overview of diabetes

Diabetes mellitus, commonly known as diabetes, is an incurable chronic health condition in which dangerously high levels of glucose flood the body due to the lack of insulin production (type 1 diabetes) or the body’s inability to use insulin to regulate blood sugar levels (type 2 and gestational diabetes). Globally, the number of people suffering from this chronic disease amounted to 537 million in 2021. The largest number of diabetics were from China, followed by India and Pakistan in that year. In terms of diabetes prevalence, French Polynesia, Mauritius, and Kuwait had the highest rates. With regard to diabetes-related health expenditure, China alone spent over half of the amount spent by the entire Western Pacific region.

Key figures of diabetes in China

Back in the 1980s, less than one percent of the Chinese population was said to have diabetes. In the recent decade, the prevalence rate has jumped to an alarming level, and about one in five of all adult diabetes sufferers worldwide were in China. Records from 2021 show that most of such patients in the country fell within the age group of 20 to 79 years - mainly type 2 diabetes. Some experts point out the nation’s economic growth coupled with unhealthy diets and reduced physical activity as major risk factors which cause type 2 diabetes. It is worth noting that the awareness and control rates of diabetes were relatively low in China compared with the situations in other strong economies.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.